Genexine Seeks China Entry Through Multi-Biologic Tasly Tie-Up
This article was originally published in PharmAsia News
South Korean biotech firm Genexine is broadening its presence in Asia. Following an agreement earlier this month with Kalbe Farma to set up a joint venture in Indonesia, it has now signed a licensing out deal for protein therapies with a subsidiary of China’s Tasly Pharmaceutical.
Register for our free email digests: